Kalytera to Enter Medical Cannabis Market With Focus on Treatment of Psoriasis and Menstrual Cramps

SAN FRANCISCO TEL AVIV, ISRAEL–(BUSINESS WIRE)–Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the “Company”
or “Kalytera“) today announced that it has entered into an
agreement with Beetlebung Pharma, Ltd. (“BPL“) for an option
to acquire all rights to medical cannabis products in development by BPL
for the treatment of both dermatologic diseases and women’s health.

Under this agreement, Kalytera will have the option to license from BPL
certain proprietary medical cannabis formulations, which can initially
be brought to market in jurisdictions that have already approved access
to cannabis for medical purposes. Kalytera